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Abstract 
Gastric cancer is the fourth most common cancer and the second leading cause of cancer death 
worldwide. Although the global incidence of gastric cancer has been decreased dramatically in recent 
decades, north and northwest of Iran have the highest incidence rate of gastric cancer. Whilst the 
surgical procedures for gastric cancer have been improved, there is no cure for that. The intestinal 
type of GC results from pre-neoplastic conditions including atrophic gastritis, intestinal metaplasia 
and dysplasia. Trefoil Factors Family proteins (TFFs) are small and stable molecules secreted by the 
mammalian gastrointestinal tract. TFFs constitute a family of three peptides (TFF1, TFF2and TFF3) 
that are widely expressed in a tissue specific manner in the gastrointestinal tract. Variable TFFs 
expression in gastric cancer and pre-neoplastic lesions has been found.  TFF1 has a tumor suppressor 
activity and inhibits tumorogenesis in gastric cancer. Its expression decreases in gastritis, gastric 
atrophy, dysplasia, intestinal metaplasia and gastric cancer.TFF2 has a protective effect on 
gastrointestinal epithelium.  As a prognostic factor, TFF2 expression decreases in gastric ulcer, 
chronic atrophic gastritis and gastric cancer TFF3 is considered as an oncogenic factor in gastric 
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Introduction 
Gastric Cancer (GC) remains the major health 
problem being fourth common cancer in the world 
and the second cause related to cancers. Almost 
one million new cases of GC are reported annually 
worldwide (1). Although there is declining trend 
of gastric cancer in the worldwide, new cases of 
GC are increasing in some Asian countries (2). In 
Iran, gastric cancer is the most common cause of 
mortality related to cancers in both genders(3). 
The most prevalent of gastric cancer is 
Adenocarcinoma. According to Lauren's 
histological classification, it is subdivided into 
diffuse and intestinal pathologic subtypes(4). The 
intestinal type of GC results from multistep 
inflammatory process. H-Pylori infection has been 
considered as an initiatory lesion. It can also 
progress to pre-neoplastic conditions including 
multifocal chronic atrophic gastritis, intestinal 
metaplasia and dysplasia (5). These pre-neoplastic 
lesions are frequent and increase the risk of GC 
(6). Although diagnostic and therapeutic 
approaches of GC have been improved, the 
mortality of GC is still high (7). Efficacious 
screening and early stage treatment can reduce 
mortality of gastric cancer (8). Until now there is 
no standard biomarker for early diagnosis and no 
consensus on screening programs(9). Thus, the 
valuable diagnostic biomarker seems to be 
helpful. Some classical biomarkers in early 
diagnosis of gastric cancer include CEA and 
CA19-9 that low specificity and sensitivity are 
their limitations. MicroRNAs (miR/miRNA) have 
been introduced as novel biomarkers in early 
diagnosis of GC. Several classical prognostic  
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tissues. Whilst the normal gastric tissues don’t express TFF3, it increases in intestinal metaplasia. 
Therefore, more studies are necessary to clarify the role of TFFs in GC and pre-neoplastic 
conditions. This review has focused on elucidating the important role of TFFs in gastric cancer and 
pre-neoplastic lesions. 
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markers including growth factors, cytokines, cell 
cycle regulators and apoptosis-associated factors 
have been studied, but extensive clinical trials is 
necessary prior to clinical application(10). 
Trefoil Factor Family proteins consist of three 
subtypes (TFF1, TFF2 and TFF3). They are 
thermo stable and protease-resistant proteins (1) 
being expressed and secreted in the mucous cells 
of the mammalian gastrointestinal tract (11). They 
are clustered in 50-kb on human chromosome 
21q22.3 region characterized by the presence of at 
least one 40-amino acids protein domain with three 
conserved disulfide bonds (12). The integrity of 
the gastrointestinal mucosa is maintained by 
numbers of secreted factors including Trefoil 
Factor Family (12). TFF1 and TFF2 are 
predominantly secreted in gastric mucosa, while 
TFF3 is expressed in goblet cell of the human 
intestine.TFF1 plays important roles in protection 
and repairing of mucosal barrier(13-15). Protection 
is done through the interaction of TFF1 and 
cysteine-rich domain of mucin protein to stabilize 
gastric epithelium gel layers (16-18) . Gastric 
hormone, gastrin, is positive regulator of TFF1. 
Promoter of TFF1 has gastrin responsiveness 
element which can be activated by this hormone 
(19).  It has been suggested that loss of TFF1 leads 
to development of neoplastic lesions and also 
gastric adenocarcinoma (7, 20, 21) . TFF2 is 
mainly expressed in stomach, duodenum and 
pancreas (15, 22). High levels of TFF2 would 
observe 30 minutes after ulceration and last for 10 
days (23).TFF2 up-regulates in chronic 
inflammation and has a protective effect on mucus 
and intestinal ulcers (24). On the other hand, TFF3 
mainly expresses in goblet cells of small and large 
intestines.TFF3 is positive in goblet cells of 
intestinal metaplasia, but the normal gastric 
mucosa is negative for TFF3 . This TFF protein 
subtype is necessary for promoting normal cells 
migration and preserving gastrointestinal (GI) 
mucosal integrity (7). Many studies believe that 
TFF3 hasa correlation between inflammation and 
occurrence of GI tumors (7, 25, 26).   Moreover, 
some studies implied overexpression of TFF3  has  
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has just a significant correlation with patient’s age 
and has no substantial association with other 
factors such as gender in general population (12). 
 TFFs have been known as acute phase reactant. 
They seem to have an important role in repairing 
of gastrointestinal tract (27). While TFF1 and 
TFF2 are gastric tumor suppressor genes, TFF3 
can promote gastric cancer (7).Different studies 
have reported variable changes of TFFs expression 
in gastric cancer and pre-neoplastic conditions(28-
30). This review aims to overview the precise role 
of TFFs in gastric cancer and pre-neoplastic 
lesions.. 
TFFs and H.pylori infection: 
There is a significant correlation between H. Pylori 
infection and TFFs peptides.Soutto M. 
demonstrated that TFF1 has an important role in 
suppressing helicobacter pylori inflammation in 
gastric carcinogenesis. Thus, loss of TFF1 
expression has a significant function in H.pylori- 
mediated gastric cancer (31). Another study in 
2015 indicated that TFF1 can activate H. pylori-
mediated oncogenic activation of β-catenin and 
induces carcinogenesis (21). 
It has been proposed that H.pylori infection would 
decrease the antral expression of TFF2, affected by 
promoter hypermethylation, which can lead to pre-
neoplastic events progression (32, 33). However, 
Xai et al. reported that H. pylori infection induces 
expression of TFF2 in gastric epithelium 
(34).Literatures indicated that there was no 
correlation between TFF3 expression and influence 
of H.pylori infection or inflammation in non-
malignant gastric tissues [34]. In the evaluation of 
long time influence of H.pylori infection, it was 
found that this infection could markedly elevate 
TFF1٫TFF2 and TFF3 serum levels. After treating 
and eradicating of H.pylori, TFF1 and TFF2 levels 
decreased but TFF3 serum level was not 
significantly affected by H.pylori eradication. 
Hence, high serum level of TFF3 can be proposed 
as a stable biomarker for early diagnosis of gastric 
cancer because , serum level of TFF3 remains high 
even in eradication therapy of  H.pyloriinfection ( 
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TFFs and gastric pre-neoplastic/cancer 
conditions: 
A) TFF1: 
In immunohistochemical study of gastric 
specimens including 35 chronic superficial gastritis 
samples (CSG), 35 gastric ulcers (GU), and 35 
chronic atrophic gastritis samples (CAG) results 
showed tendency decreasing of TFF1 expression in 
CSG, GU and CAG(36).There are strong evidence 
indicating that TFFs have pivotal role in oncogenic 
transformation, proliferation, migration, invasion 
and angiogenesis of human gastric cancer
(37).Song JY presented down regulation of TFF1 
expression during progression of IM type І to type 
ІІІ, and proposed this result might be associated 
with carcinogenesis (38). (38). Moreover, 
decreasing in TFF1 expression in low-grade 
dysplasia and high-grade dysplasia has been 
documented (39).TFF1 activates P53 tumor 
suppressor gene by down regulation of miR-504. 
Overexpression of miR-504 prevents the activity 
of P53 and decreases the p53-induced apoptosis. 
Also, it implicates in tumorigenesisprocess (20). 
The other study reported expression of TFF1 is 
increased in gastric ulcers but, showed reduced 
expression in gastric ulcerocancer. Then, it might 
be important to tell that it can be considered as a 
marker to differentiate malignant gastric 
ulcerocancer from gastric ulcer(40) A publication 
in 2015 implied that expression of TFF1 and its 
polymorphisms had protective effects in lymph 
node metastasis negative GC and diffuse-type GC 
(11). One of the important signaling pathways in 
gastric cancer development is JAK/STAT. It has 
been suggested JAK/STAT suppresses TFF1 
expression by the epigenetic silencing of 
GATA6transcription factor which is regulatory 
factor of TFF1 transcription and via this pathway 
attributes to cancer development (41) . 
Furthermore, reduced expression of TFF1 playsa 
significant role in gastric cancer carcinogenesis 
and it can be used as a marker of poor prognostic 
for patients with early stage gastric cancer (35) .  
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Noticeably, down-regulation of TFF1 expression 
in gastric cells decreases cell apoptosis and 
facilitates proliferation of gastric cells. Hence, over 
expression of TFF1 increases the apoptosis of 
gastric cells and inhibits their proliferation (42).On 
the other hand, hypermethylation of TFF1 
promoter which is one of the main cause of TFF1 
silencing,down-regulates TFF1 levels and involves 
in tumor formation at early stage of gastric 
tumorigenesis.In 2006, it was reported that loss of 
TFF1 is associated with intestinaltype ofgastric 
cancer (43).In support of tumor suppressor 
function of TFF1, it reduces gastrointestinal cell 
proliferation through delaying G1-S phase 
transition(44).TFF1 covalently bounds with TFIZ1 
as a heterodimer in normal human gastric mucosa 
and forms heterodimer protein. Disruption of this 
formation has deleterious effects in gastric cancer 
and it has been reported that TFF1 peptide in the 
absence of TFIZ1 is correlated with more 
migration and invasion phenotype (45). 
B) TFF2: 
 A study in 2004, evaluated trefoil factor family 
proteins expression by immunohistochemistry 
method in dyspepsia biopsy samples. According to 
this study, TFF2 mainly expresses in columnar 
cells in intestinal metaplasia. As the intestinal 
metaplasia progresses from type 1 to type 3, the 
expression of TFF2 protein would increase (46).In 
2004 Shi SQ and colleaguesconfirmed that TFF2 
expression would decrease in precancerous 
conditions and gastric cancer (47). He also showed 
decrease of TFF2 expression in gastric ulcer, 
chronic atrophic gastritis and gastric cancer in 
2006(29). TFF2 as a tumor suppressor gene has 
shown reduction in expression during gastric 
carcinogenesis(48). Studiesof TFF2 correlation and 
prognosis of gastric cancer suggest that TFF2 is 
positive in diffuse and large tumors which invaded 
to lymph nodes, so it can be considered as a 
predictor for a worse disease free survival(12, 49). 
Therefore, it could be a possible explanation for 
gastric protective role of low dose aspirin against 
GI carcinogenesis (50). TFF1 and TFF2 have a 
noticeable correlation in non-cancer tissue and gas- 
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Tric cancer (51). In 2016, Cai established that 
activity of TFF2 against gastric cancer is 
impressed by its interaction with Sp3 protein in 
cancerous cells (52). Otto and colleagues identified 
blottin as TFF2 binding protein (54). It is produced 
by gastric epithelium and seems to have a 
protective effect on gastrointestinal mucus (15, 
53). However, exact molecular and cellular 
mechanism is still unknown. So, further studies are 
required for clarifying the exact mechanism of 
TFF2 during pre-cancerous and cancerous 
conditions which might be a target for therapeutic 
purposes. 
C) TFF3: 
TFF3 mRNA expression is significant in gastric 
biopsy with intestinal metaplasia compared to 
normal gastric biopsy (51).TFF3 expression is 
decreased in the progression of intestinal 
metaplasia from type І to type ІІІ (46). Reduced 
expression of TFF3 in intestinal metaplasia is 
significant(54).High expression of TFF3 in early 
stage of gastric cancer has been reported, and it has 
been suggested that perhaps this peptide is an 
independent marker of poor prognosis
(35).Otherwise, Leung reported there was no 
significant difference in expression of TFF3 
between gastric cancer and normal gastric tissues. 
This controversy with other studies might be 
related to small sample size in study (39). 
Genetic alteration of TFFs: 
Several genetic and epigenetic alternations have 
been proposed to play important roles in the 
carcinogenesis pathway(55). It has been 
documented that genetic alteration of TFF1 
contributes to gastric cancer pathogenesis. 
Deletion, and/or mutations of the TFF1 gene have 
been found in human gastric carcinomas.Somatic 
mutations in exon 1 and 2 of TFF1 has been 
reported in 16.3% of gastric carcinomas in Korean 
population (56). These mutations may alter the 
structure and function of TFF1 which can result in 
interruption of gastric mucosal barrier. 
Furthermore, site-directed mutagenesis 
experiments  were performed to determine  the fu-  
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-nctional role of TFF1 mutations, and suggested 
that TFF1 mutations contribute to malignant 
behavior of gastric cancer cells including invasion 
and loss of tumor-suppressor activity(57).  
Otherwise, the research claimed that no mutation 
identified in ninety gastric carcinoma tissues and 
concluded that point mutation of TFF1 is a rare 
event in gastric carcinogenesis (58). Hence, a large 
patient population study is essential to clarify the 
role of TFF1 somatic missense mutations in gastric 
carcinogenesis. The loss of TFF1 expression by 
Loss of Heterozygosity (LOH) of 21q23.3 region 
and DNA methylation of TFF1 promoterhas been 
identified in gastric tumors (58-60). Inactivation of 
TFF1 by these two mechanisms confirms the 
function of TFF1 as a gastric-specific tumor 
suppressor.However, the accurate role of TFF1 in 
gastric carcinoma pathway remains to be 
elucidated. Serum level of TFFs and screening 
test: 
Inevaluation of TFF1 and TFF2 serum levels in 
gastric cancer patients undergoing gastrectomy 
operation, it was found that serum levels of these 
peptides would dramatically decrease after the 
surgery which confirms the origin of TFF1 and 
TFF2 (54). It seems that the serum level of TFF2 is 
lower in well-differentiated gastric cancer than 
undifferentiated types (54).TFF3 serum level is 
significantly related to grade of intestinal 
metaplasia stomach and can predict the grade of 
intestinal metaplasia (8). Susumu Aikou found that 
serum level of TFFsin gastric cancer was 
significantly higher than control group 
(54).Moreover, Zhigang Huang reported serum 
level of TFF3 in intestinal type was significantly 
lower than that of diffuse type(1). On the other 
hand, Ping Xiao study showed that TFF3 
expression in normal gastric tissue is negative, but 
serum level of TFF3in lung,pancreatic and prostate 
cancer upregulates(61). Thus, further evaluation is 
required to clarifywhetherincreasing TFF3 serum 
level is specific for GC or not . 
Serum levels evaluation of TFFs, pepsinogen test, 
and anti-H. pylori IgG can be used for detecting  
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-gastric cancer that Aiko’s study showed TFF1 and 
TFF3 have significantly higher odds ratio than 
pepsinogen test (54). (Table1). 
Besides, studies established that combining TFF3 
and pepsinogen test has more sensitivity and 
specificity than test for pepsinogen (PG) lonely. 
This test may improve early diagnosis of gastric 
cancer(8, 54). (Table2) 
Table 2: Combining test of TFF3 with PG sensitivity increases the sensitivity to 75% but specificity 
will be decreased(51). 
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Table 1: Sensitivity and specificity of serum level of TFFs, pepsinogen test and anti-H. pylori IgG 
for detectinggastric cancer (56). 
   Sensitivity Specificity 
TFF1 
Cutoff: 1.0ng/ml 
89.6 67.7 
TFF2 
Cutoff: 4.0ng/ml 
77.6 71.4 
TFF3 
Cutoff:3.6ng/ml 
80.9 81.0 
Pepsinogen test 44.8 87.4 
Anti-HP IgG 62.3 65.1 
Criteria Sensitivity Specificity Odds ratio 
PG test (+) 37.50% 81.08% 2.57 
TFF3 (≥42ng/ml) 66.67% 83.78% 10.33 
33. Michelis R, Sela S, Sbeit W, Cohen HI, Reshef R. Decreased TFF2 expression in the gastric antrum in patients 
infected with CagA-positive Helicobacter pylori. Isr Med Assoc J. 2009;11(1):11-5.  
www.imaqpress.com  
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Conclusions: 
Although the exact molecular mechanisms of TFFs are not well-understood, many studies have been 
implied the key role of TFFs in Gastric cancer. HypermethylatedCPG islands of TFF1 and TFF2 in 
DNA of tumor tissues might be useful in GC diagnosis.TFF1 can be used as therapeutic target of 
gastric cancer, since its involvement in cell migration and metastasis through TFF1 binding has been 
demonstrated. Otherwise, correlation between TFF3 and tumor invasion has been reported. Thus,TFF3 
as a stable biomarker might be considered for early diagnosis of GC.Further investigation can improve 
the prospective of molecular mechanisms and clinical applications of TFFs (7, 15). 
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